关注
sophie matheron
sophie matheron
AP-HP, Université Paris 7 Denis Diderot, INSERM UMR1137 IAME
在 aphp.fr 的电子邮件经过验证
标题
引用次数
引用次数
年份
Evidence of sexual transmission of Zika virus
E D’Ortenzio, S Matheron, X de Lamballerie, B Hubert, G Piorkowski, ...
New England Journal of Medicine 374 (22), 2195-2198, 2016
8192016
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study
V Di Martino, P Rufat, N Boyer, P Renard, S Matheron, V Le Moing, ...
Hepatology 34 (6), 1193-1199, 2001
4242001
No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception
L Mandelbrot, R Tubiana, J Le Chenadec, C Dollfus, A Faye, E Pannier, ...
Clinical Infectious Diseases 61 (11), 1715-1725, 2015
3542015
Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome: efficacy of long-term …
C Leport, F Raffi, S Matheron, C Katlama, B Regnier, AG Saimot, ...
The American journal of medicine 84 (1), 94-100, 1988
3151988
Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial
JL Meynard, M Vray, L Morand-Joubert, E Race, D Descamps, G Peytavin, ...
Aids 16 (5), 727-736, 2002
3062002
High rate of acquisition but short duration of carriage of multidrug-resistant Enterobacteriaceae after travel to the tropics
E Ruppé, L Armand-Lefèvre, C Estellat, PH Consigny, A El Mniai, ...
Clinical Infectious Diseases 61 (4), 593-600, 2015
2892015
Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America
Antiretroviral Therapy Cohort Collaboration
Clinical Infectious Diseases 41 (12), 1772-1782, 2005
2872005
Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex
E Dournon, W Rozenbaum, C Michon, C Perronne, P De Truchis, ...
The Lancet 332 (8623), 1297-1302, 1988
2531988
Identification of a highly divergent HIV type 2 and proposal for a change in HIV type 2 classification
F Damond, M Worobey, P Campa, I Farfara, G Colin, S Matheron, ...
AIDS research and human retroviruses 20 (6), 666-672, 2004
2322004
Cellular and plasma viral load in patients infected with HIV-2
F Simon, S Matheron, C Tamalet, I Loussert-Ajaka, S Bartczak, JM Pépin, ...
Aids 7 (11), 1411-1418, 1993
2231993
Efficacy and tolerance of intravitreal ganciclovir in cytomegalovirus retinitis in acquired immune deficiency syndrome
I Cochereau-Massin, P Lehoang, M Lautier-Frau, L Zazoun, P Marcel, ...
Ophthalmology 98 (9), 1348-1355, 1991
2071991
Long-term mortality in HIV-positive individuals virally suppressed for> 3 years with incomplete CD4 recovery
FN Engsig, R Zangerle, O Katsarou, F Dabis, P Reiss, J Gill, K Porter, ...
Clinical infectious diseases 58 (9), 1312-1321, 2014
1982014
Hiv-2 molecular epidemiology
B Visseaux, F Damond, S Matheron, D Descamps, C Charpentier
Infection, Genetics and Evolution 46, 233-240, 2016
1862016
Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus–1 transmission in France
MJ Mayaux, JP Teglas, L Mandelbrot, A Berrebi, H Gallais, S Matheron, ...
The Journal of pediatrics 131 (6), 857-862, 1997
1601997
Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infections
JC Melchior, G Raguin, A Boulier, E Bouvet, D Rigaud, S Matheron, ...
The American journal of clinical nutrition 57 (5), 614-619, 1993
1591993
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome
P Lehoang, B Girard, M Robinet, P Marcel, L Zazoun, S Matheron, ...
Ophthalmology 96 (6), 865-874, 1989
1501989
Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations
L Musset, O Bouchaud, S Matheron, L Massias, J Le Bras
Microbes and infection 8 (11), 2599-2604, 2006
1492006
HFRS after a wild rodent bit in the Haute-Savoie-and risk of exposure to Hantaan-like virus in a Paris laboratory.
E Dournon, B Moriniere, S Matheron
1441984
HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
B Roquebert, F Damond, G Collin, S Matheron, G Peytavin, A Benard, ...
Journal of antimicrobial chemotherapy 62 (5), 914-920, 2008
1412008
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors
D Desbois, B Roquebert, G Peytavin, F Damond, G Collin, A Bénard, ...
Antimicrobial agents and chemotherapy 52 (4), 1545-1548, 2008
1412008
系统目前无法执行此操作,请稍后再试。
文章 1–20